Moderna doses 1st patients in COVID-19 vaccine booster trial

By The Science Advisory Board staff writers

March 11, 2021 -- Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.

The new candidate, messenger RNA (mRNA)-1273.351, encodes the prefusion stabilized spike protein of the SARS-CoV-2 variant B.1.351, first identified in South Africa, and is being assessed as a booster vaccine to increase the response to emerging SARS-CoV-2 variants. The company is also investigating a second, multivalent candidate, mRNA-1273.211, that is a combination of mRNA-1273 and mRNA-1273.351.

Through a phase II clinical trial amendment, the company will enroll 60 participants previously vaccinated with mRNA-1273 to receive a single booster dose of either 20 or 50 µg of mRNA-1273.351 or 50 micrograms of mRNA-1273.211. Through a separate amendment, participants are also being offered a booster dose of 50 µg of mRNA-1273.

Concurrently, the U.S. National Institute of Allergy and Infectious Diseases is planning to conduct a phase I trial to assess the monovalent and multivalent modified mRNA-1273 vaccines as a primary series in naïve individuals, and as a booster vaccine in those previously vaccinated with mRNA-1273.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here